Inmed Pharmaceuticals Inc. · NASDAQ:INM
Inmed Pharmaceuticals — Investor Presentation (April 2021)
22 slides from Inmed Pharmaceuticals's investor presentation, Apr 28, 2021
Slide 1: Unlocking the Potential of Cannabinoid Medicines
U N L O C K I N G T H E P O T E N T I A L O F C A N N A B I N O I D M E D I C I N E S Company Webinar April 2021 :IN :I NM *common shares to be delisted from the TSX on or about May 7, 2021 www.inmedpharma.com
Slide 2: Forward Looking Statements
Forward Looking Statements This presentation contains forward - looking statements and forward - looking information within the meaning of applicable securities laws (collectively, “forward - looking statements”) including, among others, statements concerning: unlocking the full potential of cannabi
Slide 3: Today's Presenters
3 Er i c A . A dam s, MIB S Chief Executive Officer Br u ce S. Co l w ill, C P A , CA Chief Financial Officer 30+ years of experience in global biopharma leadership: business development, sales, marketing, a n d M & A w it h e n G e n e, Q L T , A bb o t t , F r e s e n i u s 25+ years of financial
Slide 4: A Differentiated Cannabinoid Pharmaceutical Company
A Differentiated Cannabinoid Pharmaceutical Company Focused on the Therapeutic Application of Cannabinoids for the Treatment of Diseases with High Unmet Medical Needs Researching the therapeutic potential of rare cannabinoids beginning with cannabinol ( CBN ) Selecting innovative, topically applied
Slide 5: Wide Range of Medicinal Properties
Wide Range of Medicinal Properties - Primarily based on non - clinical research CBC, CBD, CBDa , CBG, CBN, THC, THCa Inflammation Arthritis CBC, CBD, CBN, THC, THCv Pain CBC, CBD, CBN, THC Insomnia CBD, CBN, THC Fibromyalgia CBD, THC Spinal injury Phantom limb Migraine/headache Cramps THC Sleep apne
Slide 6: Tapping into the Potential of Rare Cannabinoids
6 Note: lists are not exhaustive Tapping into the Potential of Rare Cannabinoids 100+ Rare Cannabinoids 2 – 20% <1% Major Cannabinoids THC CBD • Epilepsy • Anxiety • Stress Disorder • Pain • Inflammation • Nausea • Stress Disorder • Sleep Apnea CBG, CBGA, CBGV, CBGVA, THC, THCA, THCVA, CBC, CBCV, CB
Slide 7: Progress with IntegraSyn
Progress with IntegraSyn Ρ 7
Slide 8: Limitations of Traditional Cannabinoid Production Approaches
8 Limitations of Traditional Cannabinoid Production Approaches Bioburden/stress on microbe may limit final yields May not produce bio - identical cannabinoid depending on cannabinoid complexity BIOSYNTHESIS CHEMICAL SYNTHESIS EXTRACTION Access to rare cannabinoids prohibitively expensive
Slide 9: IntegraSyn: Biosynthesis Evolved
9 IntegraSyn Ρ is InMed’s integrative cannabinoid manufacturing approach IntegraSyn Ρ : Biosynthesis Evolved Minimizes bioburden on fermentation microbe Flexibility to shift from production of one cannabinoid to a range of cannabinoids Optimized steps to produce high - yield, pharma - grade cannabin
Slide 10: IntegraSyn Achieves g/L Cannabinoid Yield
10 IntegraSyn Ρ Achieves 2 g/L Cannabinoid Yield 2021 • Achieved 2g/L cannabinoid yield with IntegraSyn Ρ • Signals commercial viability and supports large - scale production • Yields higher than current industry standards • Lowered overall manufacturing costs through process optimization • Enables
Slide 11: Targeting Pharmaceutical Quality Cannabinoids
2021 Targeting Pharmaceutical Quality Cannabinoids More about GMP manufacturing types in the Learn section of our website.
Slide 12: IntegraSyn: High-level Time & Event Schedule
12 GMP – Good Manufacturing Practices IntegraSyn TM : High - level Time & Event Schedule 2021 Achieve 2g/L cannabinoid yield, signaling commercial viability Continue to identify potential partnerships for IntegraSyn TM with commercial cannabinoid manufacturers Optimize pathways for production of add
Slide 13: INM-755 for Epidermolysis Bullosa (EB)
INM - 755 for Epidermolysis Bullosa (EB) 11
Slide 14: Epidermolysis Bullosa (EB)
Epidermolysis Bullosa (EB) 14 • Epidermolysis bullosa (EB) is a group of rare genetic skin diseases characterized by fragile skin that blisters easily from minimal friction that causes shearing of the skin layers. • The most common form is EB Simplex (EBS), ~55% of all EB patients. • The affected po
Slide 15: Clinical Trial Applications Filed in Multiple Countries for Phase 2 in EB
Clinical Trial Applications Filed in Multiple Countries for Phase 2 in EB 2021 • CTA filings submitted in Austria, Israel, and Serbia for a Phase 2 Clinical Trial with INM - 755 cream • Additional submissions slated for France, Germany, Greece, and Italy during the next several weeks. • Anticipated
Slide 16: INM-755: High-Level Time/Event Schedule
INM - 755: High - Level Time/Event Schedule 16 2021 Report results from 755 - 102 - HV Finalize and file regulatory submissions (CTAs) for 755 - 201 - EB trial Finalize manufacturing methods and process to support 755 - 201 - EB Produce clinical trial supplies Initiate 755 - 201 - EB trial in multip
Slide 17: INM-088 for Glaucoma
INM - 088 for Glaucoma 14
Slide 18: Potential Roles for CBN in Glaucoma
Potential Roles for CBN in Glaucoma • Direct neuroprotection for the retina and optic nerve, independent of intraocular pressure (IOP) reduction • Reduce IOP in the affected eyes via increased fluid drainage Target Effects of CBN Build Up of Aqueous Humor Fluid Optic N e r v e Pressure R e t in a Se
Slide 19: INM-088: High-Level Time/Event Schedule
19 INM - 088: High - Level Time/Event Schedule Engage leading ocular clinical research organization to develop clinical game plan Scale - up INM - 088 drug product (CBN+MiDROPS®) Publish key CBN data in peer - reviewed journal Conduct non - GLP dose ranging studies Complete pre - IND package and FDA
Slide 20: Business Development: Collaborations and Partnerships
Nature of Relationship InMed will explore the therapeutic potential in neuroprotection of specific cannabinoid analog compounds chosen from BayMedica’s library. BayMedica will assess the potential of InMed’s high - efficiency enzymes for the production of cannabinoids in its manufacturing technologi
Slide 21: Key Accomplishments and Goals
21 Key Accomplishments and Goals Highlights from 2020 Key Goals for 2021 INM - 755 in Dermatology Completed 2 Phase 1 human clinical trials (normal and wounded skin) Initiate and begin enrollment of EB patients in Ph 2 trial INM - 088 in Ocular Disease Completed in vivo PoC , formulation/ delivery s
Slide 22: Q&A Session
Q&A Session Eric A. Adams Chief Executive Officer eadams@inmedpharma.com +1 - 604 - 669 - 7207 Bruce S. Colwill Chief Financial Officer bcolwill@inmedpharma.com +1 - 604 - 669 - 7207 :IN :I NM *common shares to be delisted from the TSX on or about May 7, 2021 www.inmedpharma.com Edison Grou p Joseph
InMed Pharmaceuticals — Investor Presentation (April 2021) on 6ix